Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:52:55.558Z.
Calculation as of: 2026-10-06T17:52:55.558Z.
Quote observation: 2026-10-06T17:50:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Prelude Therapeutics Incorporated
Market Cap
$211.79M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.64M
EV/EBIT Ratio
17.44x
TTM Avg
25.81x
3Y Avg
146.27x
5Y Avg
146.27x
Market Cap
$208.47M
EV/EBIT Ratio
N/A
TTM Avg
23.42x
3Y Avg
23.28x
5Y Avg
23.28x
Market Cap
$216.82M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $211.79M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $211.33M | 6.74x | 6.24x | 9.86x | 9.86x |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.30M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 17.44x | 25.81x | 146.27x | 146.27x |
| Electra Therapeutics Inc. (ETRA)vs › | $208.65M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $208.63M | 16.82x | 15.79x | 14.74x | 15.50x |
| Entrada Therapeutics, Inc. (TRDA)vs › | $208.47M | N/A | 23.42x | 23.28x | 23.28x |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $206.05M | N/A | 19.40x | 19.40x | 19.40x |
| Sionna Therapeutics, Inc. (SION)vs › | $205.81M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
